Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Blood Rev. 2010 Feb 11;24(2):69–82. doi: 10.1016/j.blre.2010.01.001

Table 8.

Histone deacetylase inhibitors in NHL.

Study Status Agent Regimens Patients Results (%)
ORR CR/CRu
Duvicet al. [138] Phase II Vorinostat 400 mg QD Relapsed/refractory CTCL (n = 13) 31 0
Olsen et al. [139] Phase IIB Vorinostat 400 mg QD Relapsed/refractory CTCL (n = 74) 30 1
Piekarz et al. [143] Phase II Romidepsin 14 mg/m2 on days 1, 8 and 15 of a 28 days cycle Relapsed/refractory CTCL or PTCL (n = 46) 28 7
Gimsing et al. [140] Phase I Belinostat 1000 mg/m2 on days 1–5 of a 21 days cycle Relapsed/refractory hematological malignancies (n = 16) 0 0 (5 of 16 patients with SD)
Ellis et al. [141] Phase I Panobinostat 20 mg on days 1, 3, 5 weekly, every 28 days cycle Relapsed/refractory CTCL (n = 10) 60 20
Duvicet al. [142] Phase II Panobinostat 20 mg on days 1, 3, 5 weekly, every 28 days cycle Relapsed/refractory CTCL (n = 95) 16 2

CR – complete response; CRu – complete response unconfirmed; CTCL – cutaneous T-cell lymphoma; NHL – non–Hodgkin lymphoma; ORR – overall response rate; PTCL – peripheral T-cell lymphoma; SD – stable disease.